Reaction-aware molecular representation learning: Toward generalizable artificial intelligence for enzymatic catalysis

Acta Pharmaceutica Sinica B · Published 2026-07-01 · DOI 10.1016/j.apsb.2026.06.033

Free full text

Authors (1)

Kelin Xia

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2026

Citation

Xia, K. (2026). Reaction-aware molecular representation learning: Toward generalizable artificial intelligence for enzymatic catalysis. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.06.033

Related articles

• Inflammation in atherosclerosis: drivers, mechanisms and therapies · Acta Pharmaceutica Sinica B · 2026 · Same journal
• Stimulate-and-retain hydrogel strategy integrating oncolytic virus and oxaliplatin for dual ICD-inducing antitumor immunity · Acta Pharmaceutica Sinica B · 2026 · Same journal
• Modulating macrophage efferocytosis: Drug delivery strategies for enhancement, mimicry, and inhibition · Acta Pharmaceutica Sinica B · 2026 · Same journal
• Editor Profiles: Guest Editors of the Special Column on Machine Learning in Drug Discovery · Acta Pharmaceutica Sinica B · 2026 · Same journal
• Targeting senescent cells with dipeptidyl peptidase 4–CAR–NK cells alleviates liver fibrosis and reverses metabolic dysfunction · Acta Pharmaceutica Sinica B · 2026 · Same journal
• SARS-CoV-2 inhibits EBV-dependent tumor proliferation through PLpro-mediated degradation of EBNA1 · Acta Pharmaceutica Sinica B · 2026 · Same journal
• Nano-drug delivery systems of natural products in cardiovascular therapy: From mechanistic insights to precision targeting · Acta Pharmaceutica Sinica B · 2026 · Same journal
• Neuroprotection by YZG-331 in postoperative cognitive dysfunction via Mg2+-dependent blockade of NMDA receptors · Acta Pharmaceutica Sinica B · 2026 · Same journal
• Unveiling the mechanisms of comorbidity of aging and depression: A perspective based on early life stress (ELS) · Acta Pharmaceutica Sinica B · 2026 · Same journal
• A peptide-based nano-PROTAC synergistically driving ferroptosis-immunotherapy in triple-negative breast cancer · Acta Pharmaceutica Sinica B · 2026 · Same journal